Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection.

Skeate JG, Porras TB, Woodham AW, Jang JK, Taylor JR, Brand HE, Kelly TJ, Jung JU, Da Silva DM, Yuan W, Kast WM.

J Gen Virol. 2016 Feb;97(2):422-34. doi: 10.1099/jgv.0.000341. Epub 2015 Nov 10.

2.

The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection.

Woodham AW, Da Silva DM, Skeate JG, Raff AB, Ambroso MR, Brand HE, Isas JM, Langen R, Kast WM.

PLoS One. 2012;7(8):e43519. doi: 10.1371/journal.pone.0043519. Epub 2012 Aug 22.

3.

Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism.

Fakioglu E, Wilson SS, Mesquita PM, Hazrati E, Cheshenko N, Blaho JA, Herold BC.

J Virol. 2008 Oct;82(19):9337-44. doi: 10.1128/JVI.00603-08. Epub 2008 Jul 30.

4.

Human papillomavirus infection in head and neck cancer: the role of the secretory leukocyte protease inhibitor.

Hoffmann M, Quabius ES, Tribius S, Hebebrand L, Görögh T, Halec G, Kahn T, Hedderich J, Röcken C, Haag J, Waterboer T, Schmitt M, Giuliano AR, Kast WM.

Oncol Rep. 2013 May;29(5):1962-8. doi: 10.3892/or.2013.2327. Epub 2013 Mar 5.

5.

Small molecule inhibitors of the annexin A2 heterotetramer prevent human papillomavirus type 16 infection.

Woodham AW, Taylor JR, Jimenez AI, Skeate JG, Schmidt T, Brand HE, Da Silva DM, Kast WM.

J Antimicrob Chemother. 2015;70(6):1686-90. doi: 10.1093/jac/dkv045. Epub 2015 Feb 23.

6.

Vimentin Modulates Infectious Internalization of Human Papillomavirus 16 Pseudovirions.

Schäfer G, Graham LM, Lang DM, Blumenthal MJ, Bergant Marušič M, Katz AA.

J Virol. 2017 Jul 27;91(16). pii: e00307-17. doi: 10.1128/JVI.00307-17. Print 2017 Aug 15.

7.

The antileukoprotease secretory leukocyte protease inhibitor (SLPI) and its role in the prevention of HPV-infections in head and neck squamous cell carcinoma.

Quabius ES, Görögh T, Fischer GS, Hoffmann AS, Gebhard M, Evert M, Beule A, Maune S, Knecht R, Óvári A, Durisin M, Hoppe F, Röcken C, Hedderich J, Ambrosch P, Hoffmann M.

Cancer Lett. 2015 Feb 1;357(1):339-345. doi: 10.1016/j.canlet.2014.11.043. Epub 2014 Nov 24.

PMID:
25462861
8.

Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression.

Woodham AW, Raff AB, Raff LM, Da Silva DM, Yan L, Skeate JG, Wong MK, Lin YG, Kast WM.

J Immunol. 2014 May 15;192(10):4748-57. doi: 10.4049/jimmunol.1303190. Epub 2014 Apr 9.

10.

The Cytoskeletal Adaptor Obscurin-Like 1 Interacts with the Human Papillomavirus 16 (HPV16) Capsid Protein L2 and Is Required for HPV16 Endocytosis.

Wüstenhagen E, Hampe L, Boukhallouk F, Schneider MA, Spoden GA, Negwer I, Koynov K, Kast WM, Florin L.

J Virol. 2016 Nov 14;90(23):10629-10641. doi: 10.1128/JVI.01222-16. Print 2016 Dec 1.

11.

Annexin A2 and S100A10 regulate human papillomavirus type 16 entry and intracellular trafficking in human keratinocytes.

Dziduszko A, Ozbun MA.

J Virol. 2013 Jul;87(13):7502-15. doi: 10.1128/JVI.00519-13. Epub 2013 May 1.

12.

The role of the antileukoprotease SLPI in smoking-induced human papillomavirus-independent head and neck squamous cell carcinomas.

Quabius ES, Möller P, Haag J, Pfannenschmidt S, Hedderich J, Görögh T, Röcken C, Hoffmann M.

Int J Cancer. 2014 Mar 15;134(6):1323-34. doi: 10.1002/ijc.28462. Epub 2013 Sep 23.

13.

Human papillomavirus infection is inhibited by host autophagy in primary human keratinocytes.

Griffin LM, Cicchini L, Pyeon D.

Virology. 2013 Mar 1;437(1):12-9. doi: 10.1016/j.virol.2012.12.004. Epub 2013 Jan 4.

14.

Cervical Local Immune Response for High-Risk Human Papillomavirus Infection: Involvement With Cervical Mucus SLPI Proteins.

Sahin E, Madendag Y, Sahin ME, Madendag IC, Acmaz G, Karakukcu C, Karaman H, Muderris II.

Cancer Control. 2018 Jan-Dec;25(1):1073274818798598. doi: 10.1177/1073274818798598.

15.

Essential roles for soluble virion-associated heparan sulfonated proteoglycans and growth factors in human papillomavirus infections.

Surviladze Z, Dziduszko A, Ozbun MA.

PLoS Pathog. 2012 Feb;8(2):e1002519. doi: 10.1371/journal.ppat.1002519. Epub 2012 Feb 9.

16.

Superinfection Exclusion between Two High-Risk Human Papillomavirus Types during a Coinfection.

Biryukov J, Meyers C.

J Virol. 2018 Mar 28;92(8). pii: e01993-17. doi: 10.1128/JVI.01993-17. Print 2018 Apr 15.

17.

Secretory leukocyte protease inhibitor inhibits expression of polymeric immunoglobulin receptor via the NF-κB signaling pathway.

Mikami Y, Iwase T, Komiyama Y, Matsumoto N, Oki H, Komiyama K.

Mol Immunol. 2015 Oct;67(2 Pt B):568-74. doi: 10.1016/j.molimm.2015.07.021. Epub 2015 Aug 1.

18.

Activation of NF-κB by human papillomavirus 16 E1 limits E1-dependent viral replication through degradation of E1.

Nakahara T, Tanaka K, Ohno S, Egawa N, Yugawa T, Kiyono T.

J Virol. 2015 May;89(9):5040-59. doi: 10.1128/JVI.00389-15. Epub 2015 Feb 25.

19.

HPV16-E2 protein modifies self-renewal and differentiation rate in progenitor cells of human immortalized keratinocytes.

Domínguez-Catzín V, Reveles-Espinoza AM, Sánchez-Ramos J, Cruz-Cadena R, Lemus-Hernández D, Garrido E.

Virol J. 2017 Apr 3;14(1):65. doi: 10.1186/s12985-017-0736-2.

20.

Hypoxia down-regulates expression of secretory leukocyte protease inhibitor in bronchial epithelial cells via TGF-β1.

Påhlman LI, Jögi A, Gram M, Mori M, Egesten A.

BMC Pulm Med. 2015 Mar 7;15:19. doi: 10.1186/s12890-015-0016-0.

Supplemental Content

Support Center